VRTX

Vortex Energy Corp. Sends Core Samples from the Robinsons River Salt Project to the University of Alberta

Retrieved on: 
Tuesday, April 16, 2024
Core, VRTX, University, Diffusion, Energy-dispersive X-ray spectroscopy, EDS, News, Mineral, X-ray scattering techniques, Technical report, XRD, Consultant, National Instrument 43-101, Scanning electron microscope, National instrument, Quality control, Financial adviser

VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) (“Vortex” or the “Company”) is pleased to announce that it has shipped core samples from the initial hole drilled at the Robinsons River Salt Project to the University of Alberta.

Key Points: 
  • VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) (“Vortex” or the “Company”) is pleased to announce that it has shipped core samples from the initial hole drilled at the Robinsons River Salt Project to the University of Alberta.
  • The Company’s consultant, RESPEC Consulting Inc. (“RESPEC”), has conducted core logging on the cap rock and salt sections obtained from Core Hole 1 (VTX-West-23-1).
  • The cap rock is predominantly anhydrite, intermixed with mudstones, while the salt rock is primarily composed of halite, featuring zones of intermixed mudstones and occasional potash salts such as carnallite and possibly sylvite.
  • RESPEC has selected and shipped samples to the University of Alberta, which will perform various tests to delineate the material properties of the cap rock and salt.

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Retrieved on: 
Thursday, April 18, 2024
Health, FDA, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, VRTX, Pain, Pregabalin, Safety, NDA, Food, New Drug Application, DPN, Sciatica, Fast track (FDA), Week, Patient, Medicine, Neuropathic pain, LSR, Vertex, Vertex Pharmaceuticals, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades.
  • Following the positive Phase 3 results in acute pain announced in January 2024, the Food and Drug Administration (FDA) has granted a rolling New Drug Application (NDA) submission for suzetrigine in moderate-to-severe acute pain.
  • Suzetrigine was previously granted FDA Fast Track and Breakthrough Therapy designations in moderate-to-severe acute pain.
  • The company intends to advance its next generation NaV1.8 pain signal inhibitor VX-993 oral formulation into Phase 2 acute pain and peripheral neuropathic pain studies later this year.

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older

Retrieved on: 
Friday, April 26, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, VRTX, National Health Service, European Commission, Cystic fibrosis, CFTR, Life, European, Disease, Patient, Civil service commission, MHRA, Medication, Vertex Pharmaceuticals, Pharmaceutical industry

“Today’s approval is an important milestone for the cystic fibrosis community.

Key Points: 
  • “Today’s approval is an important milestone for the cystic fibrosis community.
  • As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor) shortly following regulatory approval by the European Commission.
  • Vertex will continue to work with reimbursement authorities across the European Union to ensure access for all other eligible patients.
  • In the U.K., following MHRA approval at the end of 2023, and as a result of the existing reimbursement agreement between Vertex and the National Health Service, eligible infants ages 1 month and older in the U.K. have access to this expanded indication for KALYDECO® (ivacaftor).

VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

Retrieved on: 
Tuesday, April 23, 2024
Doctor of Philosophy, VRTX, Vertex Pharmaceuticals, Cell, Patient, Biology, Therapy, Tree, Pharmaceutical industry

TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.

Key Points: 
  • TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.
  • TreeFrog's proprietary technology platform, C-Stem™, is designed to mimic the natural microenvironment, allowing cells to grow exponentially in 3D.
  • The technology will enhance Vertex's ability to generate large amounts of fully differentiated cells for its portfolio of T1D cell therapies.
  • "This collaboration with Vertex advances our business strategy of helping bring best-in-class cell therapies to millions of people — both through our own therapeutic programs, and with best-in-class partners like Vertex.

VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

Retrieved on: 
Tuesday, April 23, 2024
Doctor of Philosophy, VRTX, Vertex Pharmaceuticals, Cell, Patient, Biology, Therapy, Tree, Pharmaceutical industry

TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.

Key Points: 
  • TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.
  • TreeFrog's proprietary technology platform, C-Stem™, is designed to mimic the natural microenvironment, allowing cells to grow exponentially in 3D.
  • The technology will enhance Vertex's ability to generate large amounts of fully differentiated cells for its portfolio of T1D cell therapies.
  • "This collaboration with Vertex advances our business strategy of helping bring best-in-class cell therapies to millions of people — both through our own therapeutic programs, and with best-in-class partners like Vertex.

Vortex Energy Announces Drilling Update and $115,500 Grant Award At The Robinsons River Salt Project

Retrieved on: 
Tuesday, April 9, 2024
Government, Project, Vortex, FTE, VRTX, Weather

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) (“Vortex” or the “Company”) is pleased to announce the completion of drill planning for the third exploration drillhole at the Robinsons River Salt Project (the “Project”).

Key Points: 
  • VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) (“Vortex” or the “Company”) is pleased to announce the completion of drill planning for the third exploration drillhole at the Robinsons River Salt Project (the “Project”).
  • Furthermore, Vortex has been awarded a $115,500 grant from the Government of Newfoundland and Labrador, Department of Industry, Energy and Technology Mineral Incentive Program – Junior Exploration Assistance program.
  • This grant is in recognition of prior exploration expenditures made on the Project.
  • Paul Sparkes, CEO of Vortex Energy Corp., commented, “We are thrilled to be advancing our exploration efforts at the Project.

Vortex Energy Closes Charity Flow-Through Private Placement for Gross Proceeds of C$830,000

Retrieved on: 
Tuesday, March 26, 2024
Income Tax Act, Offering, VRTX, Security (finance)

VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) ("Vortex” or the "Company") is pleased to announce that it has closed its previously announced non-brokered charity flow-through private placement of common shares of the Company (the “Offering”) for gross proceeds to the Company of C$830,000.52 pursuant to an arrangement with Wealth Creation Preservation & Donation Inc. (“WCPD”).

Key Points: 
  • VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) ("Vortex” or the "Company") is pleased to announce that it has closed its previously announced non-brokered charity flow-through private placement of common shares of the Company (the “Offering”) for gross proceeds to the Company of C$830,000.52 pursuant to an arrangement with Wealth Creation Preservation & Donation Inc. (“WCPD”).
  • Pursuant to the Offering, the Company issued 2,441,178 “flow-through” common shares of the Company (each, a “Flow-Through Share”) at a price of C$0.34 per Flow-Through Share.
  • The Flow-Through Shares issued under the Offering are intended to qualify as “flow through shares” within the meaning of the Income Tax Act (Canada) (the “Tax Act”).
  • All securities issued in connection with the closing of the Offering are subject to a statutory hold period, in accordance with applicable securities laws, expiring on July 26th, 2024.

Vertex to Announce First Quarter 2024 Financial Results on May 6

Retrieved on: 
Tuesday, April 9, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, International, Webcast, Vertex Pharmaceuticals, Vertex, VRTX

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close.
  • The company will host a conference call and webcast at 4:30 p.m.
  • To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2024 Earnings Call.”
    The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section.
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

Retrieved on: 
Monday, April 1, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, BTD, Orphan drug, APOL1, RPD, Disease, Patient, Apolipoprotein L1, FSGS, Standard of care, EMA, UPCR, European Medicines Agency, Vertex Pharmaceuticals, Clinical trial, Vertex, Proteinuria, Food, FDA, IDMC, VRTX, Pharmaceutical industry

The clinical trial is designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with proteinuric kidney disease mediated by two variants in the APOL1 gene, known as AMKD.

Key Points: 
  • The clinical trial is designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with proteinuric kidney disease mediated by two variants in the APOL1 gene, known as AMKD.
  • In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.
  • The IDMC also recommended enrolling adolescents with AMKD ages 10 to 17 years in the Phase 3 portion of the study.
  • The European Medicines Agency (EMA) has also granted inaxaplin Priority Medicines (PRIME) and Orphan Drug designations for AMKD.

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Retrieved on: 
Thursday, March 21, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Death, Autosome, VRTX, Growth, Disease, PC1, Patient, Kidney failure, Kidney transplantation, Polycystic kidney disease, IND, Vertex Pharmaceuticals, PKD1, Vertex, ADPKD, Dialysis, Cystic fibrosis, Food, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants.
  • ADPKD is the most common inherited kidney disease, with an estimated 250,000 people in the U.S. and Europe living with ADPKD; however, there are no treatments currently available that address the underlying causal biology of the disease.
  • ADPKD is a life-shortening genetic kidney disease characterized by the growth of numerous kidney-enlarging cysts that impair kidney function and can ultimately lead to kidney failure, requiring dialysis or kidney transplantation, and premature death.
  • The majority of ADPKD cases are caused by variants in the PKD1 gene, which encodes the polycystin 1 (PC1) protein.